Making Pharmaceutical Administration Evidence Cumulative: What PBPK Teaches Us About Building Knowledge Across PBPK.

Authors

Carlos Victor Montefusco-Pereira, Howard Lopes Ribeiro Junior

Published in

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. Pages 115200. Aug 08, 2026. Epub Aug 08, 2026.

Abstract

Pharmaceutical administration studies determine whether a medicine can be prepared, held, and delivered without unacceptable loss of quality. Their conclusions are essential to product instructions, yet the underlying evidence is difficult to use beyond the product and conditions originally tested. This letter contrasts that pattern with physiologically based pharmacokinetic modelling, a field in which system, drug, and study information are represented separately and the purpose and limits of model use are made explicit. Administration science does not require a PBPK model. It does, however, need records that preserve the relationships among product and formulation attributes, administration-system components, preparation and use conditions, measured outcomes, and the boundaries of the experiment. Standardized, structured records would not remove the need for product-specific studies. They would make previous work easier to interpret, reveal when further testing is necessary, and allow administration evidence to contribute to cumulative pharmaceutical knowledge.

PMID:
42570821
Bibliographic data and abstract were imported from PubMed on 09 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.